HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD tells Metabolic Research to drop claims

This article was originally published in The Tan Sheet

Executive Summary

Metabolic Research disagrees with the National Advertising Division's recommendations to discontinue claims that people who take Stemulite experience "deep REM sleep, Increased Muscle Gain and Endurance, Increased Wellness and Energy." The firm said data in the New England Journal of Medicine and "similar resources" supports the claims. It added it "retained counsel to further review" claim documentation and has "every intention" of complying. NAD said a 17-person, 30-day study Metabolic Research submitted did not support the claims because it was too small, subjective and not placebo-controlled. The two got off to a rocky start when NAD attempted to contact the firm via a former employee at an incorrect address. The resulting delay did not give the firm enough time to response to NAD's request, the firm said. This prompted NAD to refer the case to the Federal Trade Commission (1"The Tan Sheet" Sept. 7, 2009). NAD reopened the case after the advertiser said it would participate

You may also be interested in...

Stemulite Marketer Learns NAD Expects Prompt Replies

Stemulite fitness dietary supplements marketer Metabolic Research Inc. finds that failing to reply promptly to a National Advertising Division inquiry can get a firm tossed from the self-regulatory frying pan into the FTC fire

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts